Astellas Venture Management is a financial organisation which targets its investments in the biotechnologies. They invest in companies that are dedicated to developing new pharmaceutical seeds, or constructing a new drug discovery platform. Their investments are not limited to any geographical location.
| Company | Date | Round | Size | Participants |
| Effector Therapeutics | 5/13 | Series A | $45M | 7 |
| DecImmune Therapeutics | 2/13 | Private Equity | $2.25M | 3 |
| Bicycle Therapeutics | 12/12 | Venture Round | £3.75M | 5 |
| F2G | 9/12 | Venture Round | $30M | 6 |
| PhaseBio Pharmaceuticals | 6/12 | Series B | $23M | 5 |
| Cleave Biosciences | 10/11 | Series A | $44M | 5 |
| Verastem | 7/11 | Series B | $32M | 6 |
| DecImmune Therapeutics | 9/10 | Venture Round | $3.2M | 3 |
| Nereus Pharmaceuticals | 6/10 | Series E | $20M | 7 |
| Fate Therapeutics | 11/09 | Series B | $30M | 6 |
| Epizyme | 10/09 | Series B | $32M | 5 |
| Viamet Pharmaceuticals | 7/09 | Series B | $18M | 6 |
| Intradigm Corporation | 1/09 | Series B | $21.4M | 8 |
| F2G | 8/08 | Venture Round | £6.3M | 4 |
| Inimex Pharmaceuticals | 6/08 | Series B | $22M | 8 |
| Lectus Therapeutics | 2/06 | Series A | £8.2M | 4 |